Coming Soon! The Eversense® 365 CGM System, the world’s first and only one-year CGM, has been cleared for use in the US by the FDA and will be covered by most commercial insurance plans.

 

this is hero image

Help your patients live life uninterrupted.

Eversense E3 CGM System is the only CGM with 6 months of continuous glucose readings designed to reduce interruptions that stand in the way of optimal care.

Eversense E3 is designed to overcome the limitations of short-term CGM systems

#1 CGM in Survivability & Longevity<sup>1-3</sup>
#1 CGM in Survivability & Longevity1-3
Most Accurate in Low Glucose Ranges<sup>1-3</sup>
Most Accurate in Low Glucose Ranges1-3
Most Dependable Detection Alerts<sup>1-3</sup>
Most Dependable Detection Alerts1-3
Almost No Skin Reactions from Adhesive<sup>4</sup>
Almost No Skin Reactions from Adhesive4

The Eversense difference.

Eversense E3 is an optimal choice for adults with diabetes on insulin

Eversense solves the real-life challenges of traditional CGMs.

If your patients are experiencing:

  • Sensors falling or knocked off
  • Sensors not lasting as long as expected
  • Questioning accuracy of readings
  • Alarm fatigue
  • Skin irritation from adhesives
  • False lows or compression lows

See how Eversense E3 outlasts and outperforms traditional CGMs.

Eversense E3
Traditional CGMs2,3
Sensor Lifetime
6 months
7-14 days
Survivability Rate at Lifetime Percentage
95%
68.3-80.5%
Sensor Technology
Fluorescent
Enzymatic
MAD (mg/dL) Severe Hypo-Range**
7.5
14.2-16
Essentially No Compression Lows
Yes
No
Drug Interference
Tetracycline and Mannitol
Acetaminophen, Hydroxyurea, Ascorbic acid (Vitamin C)
Annual Sensor Insertions
2
26-36
On body vibration alerts
Yes
No
Easy-on, Easy-off Transmitter
Yes*
No
Adhesive
Silicone-based
Acrylic-based

** 40-60 mg/dL for Eversense E3. < 54 mg/dL for all others

The CGM for real life.

Eversense E3 delivers real-life benefits to you and your patients. Download our guide to learn more about the types of patients who benefit most from our 6 month CGM system.

 

Previous Device Burden: CGM falling off during exercise, unable to access phone and cannot hear alerts.

Favorite Eversense Benefit: “I don’t worry about wasting a sensor if I’m too sweaty for my CGM to stay on my skin.”

Previous Device Burden: False low glucose alarms at night, need to reduce TBR and increase hypo awareness.

Favorite Eversense Benefit: “I can sleep on my arm with nearly no false lows. When I receive an alert, I feel confident that it’s real.”

Previous Device Burden: CGM falling off during swimming, unable to monitor mobile alerts.

Favorite Eversense Benefit: “The freedom to remove my transmitter for swim practice without losing my sensor.”

Previous Device Burden: Skin irritations from short-term CGMs caused bruising.

Favorite Eversense Benefit: “The gentle, silicone adhesive that does not irritate my skin.”
DOWNLOAD GUIDE

Getting started is easy.

SEE FULL PROCESS

Step One: Prescribe the Eversense E3 CGM System

Patient referrals can be made to Ascensia Diabetes Care by:

• Parachute Health
• Fax PIF, CMN, Chart Notes and Insurance Info

Step Two: Refer your patients to the Eversense Inserter Network

Our skilled medical professionals will manage:

• Insertion and removal procedures
• Billing
• Scheduling

this is 50 | 50 image

Broad coverage for your patients

Eversense E3 is available to over 300 million covered lives in the U.S. Explore more details including Federally Funded plans and commercial plans.

SEE COVERAGE DETAILS

The Eversense PASS Program

Eligible individuals can experience CGM for only $99†, now and in the future.

this is 50 | 50 image

1. Senseonics. (2023) Eversense E3 Continuous Glucose Monitoring System User Guide. LBL-6002-01-001_Rev C
2. Dexcom. (2023) G7 User Guide. AW00078-10 Rev 002 MT-00078-10
3. Abbott. (2022) FreeStyle Libre 3 Flash Glucose Monitoring System User Manual. ART43911-001 Rev. B 06/22
4. Deiss D., et al. Real-World Safety of an Implantable Continuous Glucose Sensor Over Multiple Cycles of Use: A Post-Market Registry Study. Diabetes Technol & Ther, 2020, 22(1);48-52. DOI: 10.1089/dia.2019.0159.

* There is no glucose data generated when the transmitter is removed
† Offer does not apply to the insertion and removal procedures. The Eversense PASS Program has limitations on eligibility. Ascensia Diabetes Care reserves the right to change or terminate this program at any time without notice. The program benefit is capped per transaction. There may be instances in which out-of-pocket costs exceed what is detailed in the offer.

Disclaimer

The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more.

For safety information click here.

Eversense, Eversense E3 Continuous Glucose Monitoring and the Eversense logo are trademarks of Senseonics, Incorporated. Ascensia, and the Ascensia Diabetes Care logo are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.

Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.

 

PP-SENS-E3-GBL-0066